Disc Medicine reports APOLLO Phase 3 trial success
The company says bitopertin met all primary and secondary endpoints in the pivotal APOLLO trial in adults and adolescents with erythropoietic protoporphyria.
Story updates
11:08:26 AM UTC
SquawkNews
Disc Medicine reported the pivotal Phase 3 APOLLO trial of bitopertin in EPP/XLP met all primary and secondary endpoints. The company plans to resubmit an NDA to the FDA by end-2026, with a decision anticipated by mid-2027.Material DetailsContext by AI AnalystThis is late-stage validation of a lead…
11:13:23 AM UTC
SquawkNews
Disc Medicine announced APOLLO Phase 3 topline success: bitopertin met all primary and secondary endpoints, showing large PPIX reduction and meaningful increases in time in light without pain.Key Highlights:Original SEC Filing: Disc Medicine, Inc. [ IRON ] - 8-K - Oct. 19, 2026This is an AI-powered…